丹参联合缬沙坦对早期慢性肾衰的疗效评价

目的探讨丹参联合缬沙坦治疗早期慢性肾衰的临床疗效。方法将60例早期慢性肾衰患者随机分为对照组与观察组,每组各30例。两组患者均给予慢性肾衰常规治疗,给予对照组患者缬沙坦口服,观察组患者在缬沙坦口服基础上给予丹参注射液静点,疗程为4周。比较两组肾功能、尿微量白蛋白(ALB)、24h尿微量白蛋白排泄率(UAER)、尿微球蛋白(β-MG)、血脂及血流变学指标的改变。结果两组血清肌酐(Cr)比较差异无统计学意义(P>0.05);治疗后观察组ALB、UAER、β-MG显著低于对照组(P<0.05);血流变学指标显著优于对照组(P<0.05);血TG、TC显著低于对照组(P<0.05)。结论丹参联合缬沙坦治疗早期慢性肾衰可显著减少患者尿蛋白,改善血流变学及血脂,延缓肾功能不全的发展。

Clinical efficacy of salvia combined with Valsartan in the treatment of early chronic renal failure

Objective To explore the clinical effect of salvia combined with Valsartan in the treatment of early chronic renal failure. Methods Sixty patients with early chronic renal failure were randomly divided into the control group and the study group, with 30 patients in each group. Patients in the control group received oral administration of Valsartan based on routine treatment, while those in the study group received salvia quiescent point plus intravenous drip of Valsartan based on routine treatment. Renal function, ALB, UAER, β-MG, blood lipid and blood rheology indexes were compared between the two groups. Results There were no statistically significant difference in the levels of Cr between the two groups (P>0.05); The levels of ALB, UAER and β-MG were significantly lower in the study group than the control group (P<0.05); Blood rheology indexes in the study group were significantly better than that in the control group (P<0.05); The levels of serum TG and TC in the study group were significantly lower than that in the control group (P<0.05). Conclusion For patients with early chronic renal failure, salvia combined with Valsartan can greatly decrease urine protein, improve blood lipid and blood rheology indexes, and delay the progress of renal failure.